Visionary Holdings Inc. (NASDAQ: GV) has announced a significant $12 million exclusive distribution agreement for its 'President Super Injection' anti-aging product with Huajin China Investment Company. This deal marks a major milestone in the company's strategic pivot toward the high-margin medical aesthetics and biotechnology sectors. In a simultaneous move, the company’s board of directors approved a strategic exit from its non-core education business to streamline operations and focus resources. The divestiture is designed to allow the firm to concentrate entirely on healthcare and biotechnology innovations. Management expects the new distribution agreement to provide a substantial revenue boost and long-term growth opportunities for shareholders. This restructuring highlights Visionary Holdings' commitment to optimizing its portfolio for higher profitability and market competitiveness.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis